Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InMed Pharmaceuticals Inc.INM · Entity 8139 | CFO | January 24, 2022 | January 24, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InMed Pharmaceuticals Inc.
Report date January 24, 2022 · Filed January 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,515 |
Reported balance
After 2022-01-24 transaction · row 1
1 source rowRow 1 · 2022-01-24 · Purchase · Acquired 5,000 · Balance 11,515 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 24, 2022 Filed Jan 24, 2022 14:02 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Stock | 5,000 | $1.09 | $5,438.50 |
DisclosureSEC source: 0001213900-22-003286 · ownership.xml · nonDerivative · entry 1 COLWILL BRUCE · CIK 0001817743 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,515 Read SEC document |
| October 18, 2021 Filed Oct 19, 2021 18:18 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001213900-21-053578 · ownership.xml · derivative · entry 1 COLWILL BRUCE · CIK 0001817743 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,303 Underlying: Common shares · 60,000 shares Expires 2026-10-17 F1 · derivative.exercise_date: The options were granted on 10/18/2021 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant. Read SEC document |
| September 28, 2021 Filed Sep 29, 2021 13:59 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Stock | 5,000 | $1.77 | $8,840.00 |
DisclosureSEC source: 0001213900-21-050521 · ownership.xml · nonDerivative · entry 1 COLWILL BRUCE · CIK 0001817743 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,515 Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 06:15 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001213900-20-043358 · ownership.xml · derivative · entry 1 COLWILL BRUCE · CIK 0001817743 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common shares · 60,000 shares Expires 2025-12-15 F1 · derivative.exercise_price: The Canadian exercise price of C$3.85 was converted into U.S. dollars using an exchange rate of C$1.2753 = US$1.00. F2 · derivative.exercise_date: The options were granted on 12/16/2020 and will vest as follows: 25% on 6/16/2021; 25% on 12/16/2021; 25% on 6/16/2022; and 25% on 12/16/2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.